Treatment of anxiety disorders

B Bandelow, S Michaelis… - Dialogues in clinical …, 2017 - Taylor & Francis
Anxiety disorders (generalized anxiety disorder, panic disorder/agoraphobia, social anxiety
disorder, and others) are the most prevalent psychiatric disorders, and are associated with a …

The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature

AF Carvalho, MS Sharma, AR Brunoni… - Psychotherapy and …, 2016 - karger.com
Newer generation antidepressant drugs (ADs) are widely used as the first line of treatment
for major depressive disorders and are considered to be safer than tricyclic agents. In this …

Depression sum-scores don't add up: why analyzing specific depression symptoms is essential

EI Fried, RM Nesse - BMC medicine, 2015 - Springer
Most measures of depression severity are based on the number of reported symptoms, and
threshold scores are often used to classify individuals as healthy or depressed. This method …

Prospective validation that subgenual connectivity predicts antidepressant efficacy of transcranial magnetic stimulation sites

A Weigand, A Horn, R Caballero, D Cooke, AP Stern… - Biological …, 2018 - Elsevier
Background The optimal target in the dorsolateral prefrontal cortex for treating depression
with repetitive transcranial magnetic stimulation (rTMS) remains unknown. Better efficacy …

[HTML][HTML] Addressing the side effects of contemporary antidepressant drugs: a comprehensive review

SM Wang, C Han, WM Bahk, SJ Lee… - Chonnam medical …, 2018 - synapse.koreamed.org
Randomized trials have shown that selective serotonin reuptake inhibitors (SSRIs) and
serotonin-norepinephrine reuptake inhibitors (SNRIs) have better safety profiles than …

Psychological and interpersonal dimensions of sexual function and dysfunction

L Brotto, S Atallah, C Johnson-Agbakwu… - The journal of sexual …, 2016 - academic.oup.com
Introduction Psychological, interpersonal, and sociocultural factors play a significant role in
making one vulnerable to developing a sexual concern, in triggering the onset of a sexual …

[HTML][HTML] Zuranolone in major depressive disorder: results from MOUNTAIN—a phase 3, multicenter, double-blind, randomized, placebo-controlled trial

AH Clayton, R Lasser, I Nandy, AJ Sankoh… - The Journal of …, 2023 - psychiatrist.com
Objective: To evaluate the efficacy and safety of zuranolone, an investigational neuroactive
steroid and GABA A receptor positive allosteric modulator, in major depressive disorder …

[HTML][HTML] Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data

C Sanchez, KE Asin, F Artigas - Pharmacology & therapeutics, 2015 - Elsevier
Vortioxetine, a novel antidepressant for the treatment of major depressive disorder (MDD), is
a 5-HT 3, 5-HT 7 and 5-HT 1D receptor antagonist, 5-HT 1B receptor partial agonist, 5-HT …

Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data

RM Islam, RJ Bell, S Green, MJ Page… - The lancet Diabetes & …, 2019 - thelancet.com
Background The benefits and risks of testosterone treatment for women with diminished
sexual wellbeing remain controversial. We did a systematic review and meta-analysis to …

Risk factors for sexual dysfunction among women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015

MP McCabe, ID Sharlip, R Lewis… - The journal of sexual …, 2016 - academic.oup.com
Introduction This article presents a review of previous research concerning risk factors for
sexual dysfunction in women and men. Aim The aim is to evaluate past research studies to …